



## Consultative Expert Working Group on Research and Development: Financing and Coordination

### Draft resolution

The Sixty-fifth World Health Assembly,

PP1 Having considered the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG);<sup>1</sup>

PP2 Recalling resolution WHA63.28 which requested the Director-General, inter alia, to establish the CEWG in order to take forward the work of the Expert Working Group earlier established under resolution WHA61.21, and to submit the final report to the Sixty-fifth World Health Assembly;

PP3 Further recalling resolutions WHA59.24, WHA61.21 and WHA62.16,

1. WELCOMES the analysis of the CEWG report and expresses its appreciation to the Chair, Vice-Chair and all the members of the Working Group for their work;

2. URGES Member States:<sup>2</sup>

(1) to hold national level consultations among all relevant stakeholders in order to discuss the CEWG report and other relevant analyses resulting in concrete proposals and actions;

(2) to participate actively in the meetings at regional and global level referred to in this resolution;

(3) to implement, where feasible, in their respective countries, proposals and actions identified by national consultations;

(4) to establish and/or strengthen mechanisms for improved coordination of research and development (R&D)<sup>3</sup> in collaboration with WHO and other relevant partners, as appropriate;

---

<sup>1</sup> Documents A65/24; Annex and A65/24 Corr.1.

<sup>2</sup> And, where applicable, regional economic integration organizations.

<sup>3</sup> In the context of this resolution R&D shall refer to health research and development related to Type II and Type III diseases and the specific research and development needs of developing countries in relation to Type I diseases.

3. CALLS UPON Member States<sup>1</sup>, the private sector, academic institutions and nongovernmental organizations to increase investments in health research and development related to Type II and Type III diseases and the specific research and development needs of developing countries in relation to Type I diseases;
4. REQUESTS regional committees to discuss at their 2012 meetings the report of the CEWG in the context of the implementation of the global strategy and plan of action on public health, innovation and intellectual property<sup>2</sup> in order to contribute to concrete proposals and actions;
5. REQUESTS the Director-General to hold an open-ended Member States<sup>1</sup> meeting in order to analyse thoroughly the report and the feasibility of the recommendations proposed by the CEWG, taking into account, as appropriate, related studies. The meeting will also take into account the results from national consultations and regional committee discussions and develop proposals or options relating to (1) research coordination, (2) financing and (3) monitoring of R&D expenditures,<sup>3</sup> to be presented under a substantive item dedicated to the follow up of the CEWG report at the Sixty-sixth World Health Assembly, through the Executive Board at its 132nd session.

= = =

---

<sup>1</sup> And, where applicable, regional economic integration organizations.

<sup>2</sup> Resolutions WHA61.21 and WHA62.16.

<sup>3</sup> As defined in the Global strategy and plan of action on public health, innovation and intellectual property.

## Report on financial and administrative implications for the Secretariat of resolutions proposed for adoption by the Executive Board or Health Assembly

**1. Resolution:** Consultative Expert Working Group on Research and Development: Financing and Coordination

**2. Linkage to the Programme budget 2012–2013 (see document A64/7**  
[http://apps.who.int/gb/ebwha/pdf\\_files/WHA64/A64\\_7-en.pdf](http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_7-en.pdf))

Strategic objective(s): 11

Organization-wide expected result(s): 11.1

**How would this resolution contribute to the achievement of the Organization-wide expected result(s)?**

Access to essential medicines and medical technologies is a fundamental pillar of national medicine policies. Research and development of new medicines and technologies for effectively tackling the diseases that disproportionately affect developing countries is critical to improving access. It is also very important that new technologies, when developed, are affordable. Currently, spending on research and development is insufficient, and even when new medicines are developed they are not affordable. This resolution will support discussions and consultations among Member States on the feasibility of the recommendations of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination, in particular those concerning a binding global instrument, aimed at enhancing sustainable funding for research and development and ensuring that the resulting products and technologies are affordable.

**Does the programme budget already include the products or services requested in this resolution? (Yes/no)**  
No.

**3. Estimated cost and staffing implications in relation to the Programme budget**

**(a) Total cost**

Indicate (i) the lifespan of the resolution during which the Secretariat's activities would be required for implementation and (ii) the cost of those activities (estimated to the nearest US\$ 10 000).

(i) 1 year (covering the period 2012–2013)

(ii) Total: US\$ 1 370 000 (staff: US\$ 370 000; activities: US\$ 1 000 000)

**(b) Cost for the biennium 2012–2013**

Indicate how much of the cost indicated in 3 (a) is for the biennium 2012–2013 (estimated to the nearest US\$ 10 000).

Total: US\$ 1 370 000 (staff: US\$ 370 000; activities: US\$ 1 000 000)

Indicate at which levels of the Organization the costs would be incurred, identifying specific regions where relevant.

Headquarters and regional offices.

Is the estimated cost fully included within the approved Programme budget 2012–2013? (Yes/no)

No.

If “no”, indicate how much is not included.

US\$ 1 370 000

**(c) Staffing implications**

Could the resolution be implemented by existing staff? (Yes/no)

No.

If “no” indicate how many additional staff – full-time equivalents – would be required, identifying specific regions and noting the necessary skills profile(s), where relevant.

For the secretariat of the open-ended Member States meeting: one staff member at grade P.3 and one staff member at grade G.4 for one year.

**4. Funding**

Is the estimated cost for the biennium 2012–2013 indicated in 3 (b) fully funded? (Yes/no)

No.

If “no”, indicate the funding gap and how the funds would be mobilized (provide details of expected source(s) of funds).

US\$ 1 370 000 source(s) of funds: funding proposals will be sent to selected Member States and donor agencies.

= = =